These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2606117)

  • 21. [Electrophysiologic properties of cibenzoline in Wolff-Parkinson-White syndrome and atrioventricular nodal reentry tachycardia].
    Kühlkamp V; Ickrath O; Schmid F; Mayer F; Haasis R; Seipel L
    Z Kardiol; 1989 Oct; 78(10):640-6. PubMed ID: 2686251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiologic effects and antiarrhythmic efficacy of recainam in patients with supraventricular tachycardia.
    Tai YT; Campbell RW; McComb JM
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):310-5. PubMed ID: 1709237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
    Manz M; Lüderitz B
    Eur Heart J; 1993 Sep; 14 Suppl E():91-8. PubMed ID: 8223763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
    Follath F; Candinas R; Frielingsdorf J
    Herz; 1993 Feb; 18(1):20-6. PubMed ID: 8454249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA; Kuhn RJ; McCaffrey FM
    Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous dantrolene does not exhibit calcium channel blocking effects on the cardiac conduction system in humans.
    Kentsch M; Roewer N; Kunze KP; Kuck KH
    Anesthesiology; 1991 Oct; 75(4):583-7. PubMed ID: 1928768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical electrophysiologic effects of lorcainide in patients and its effect on the conduction of accessory pathway in Wolff-Parkinson-White syndrome].
    Jiang H
    Zhonghua Xin Xue Guan Bing Za Zhi; 1990 Jun; 18(3):157-9, 190. PubMed ID: 2086169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combination anti-arrhythmic drug therapy].
    Lüderitz B; Jung W; Manz M
    Z Kardiol; 1992; 81 Suppl 4():157-61. PubMed ID: 1283933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of sotalol for life-threatening ventricular arrhythmias.
    Roden DM
    Am J Cardiol; 1993 Aug; 72(4):51A-55A. PubMed ID: 8346727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cibenzoline: electrophysiologic effects of a new class I anti-arrhythmia agents in supraventricular tachycardia].
    Pfitzner P; Manz M; Schütz R; Lüderitz B
    Z Kardiol; 1989 Oct; 78(10):654-60. PubMed ID: 2686252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome.
    Tanel RE; Walsh EP; Lulu JA; Saul JP
    Am Heart J; 1995 Oct; 130(4):791-7. PubMed ID: 7572588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Electrophysiologic effects of betaxolol on conduction properties of the antegrade and retrograde pathway in patients with typical atrioventricular node reentry tachycardia following intravenous and oral administration].
    Kühlkamp V; Ickrath O; Haasis R; Seipel L
    Z Kardiol; 1988 Aug; 77(8):527-33. PubMed ID: 3176596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sotalol in the Wolff-Parkinson-White syndrome: an electrophysiological and clinical study].
    Inama G; Furlanello F; Vergara G; Guarnerio M; Braito G; Nassivera E
    G Ital Cardiol; 1992 Jun; 22(6):701-13. PubMed ID: 1426808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Electrophysiologic effect of intravenous propafenone in supraventricular tachycardia].
    Iturralde P; Nunura F; Romero L; Colín L; Rosado J; Galván O; de Micheli A; González Hermosillo JA; Casanova JM
    Arch Inst Cardiol Mex; 1991; 61(2):135-41. PubMed ID: 1854228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group.
    Jordaens L; Gorgels A; Stroobandt R; Temmerman J
    Am J Cardiol; 1991 Jul; 68(1):35-40. PubMed ID: 2058557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia.
    Rizos I; Senges J; Jauernig R; Lengfelder W; Czygan E; Brachmann J; Kübler W
    Am J Cardiol; 1984 Apr; 53(8):1022-7. PubMed ID: 6702678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety issues in the treatment of paediatric supraventricular tachycardias.
    Pfammatter JP; Bauersfeld U
    Drug Saf; 1998 May; 18(5):345-56. PubMed ID: 9589846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of amiodarone, sematilide, and sotalol on QT dispersion.
    Cui G; Sen L; Sager P; Uppal P; Singh BN
    Am J Cardiol; 1994 Nov; 74(9):896-900. PubMed ID: 7526675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia.
    Basta M; Klein GJ; Yee R; Krahn A; Lee J
    Cardiol Clin; 1997 Nov; 15(4):587-97. PubMed ID: 9403162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.